Trial intelligence / Profile preview

Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma

2008-004956-60Phase 2Completed

Sponsor: University College London
Start: Jun 2009
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of melphalan, alemtuzumab, etoposide, carmustine, cytarabine and 1 more in Hodgkin lymphoma (HL), sponsored by University College London. Primary endpoint: 3-year progression-free survival. Started Jun 2009; status: completed.

Drugs

melphalanalemtuzumabetoposidecarmustinecytarabine

Conditions

Hodgkin lymphoma (HL)

Beyond the preview

Go deeper on 2008-004956-60.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-004956-60.